Epithelial growth factor receptor (EGFR) mutations are common in lung cancer, and the identification of gene mutation types is becoming increasingly crucial because of the clinical efficacy of the latest generation of EGFR-targeted drugs. The gene discussed is EGFR; the disease is lung carcinoma.